Cargando…
Engineered nucleus-free mesenchymal stem cells (MSCs) for the targeted delivery of therapeutics to disease site
Autores principales: | Schwartz, Zander, Zhao, Piao, Wang, Annie, Zhao, Guozhi, Zeng, Wei, Wang, Yonghui, Luu, Hue H., Haydon, Rex C., He, Tong-Chuan, Reid, Russell R., Strelzow, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201659/ https://www.ncbi.nlm.nih.gov/pubmed/37223510 http://dx.doi.org/10.1016/j.gendis.2022.09.001 |
Ejemplares similares
-
Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk
por: Qin, Kevin, et al.
Publicado: (2023) -
SV40 large T antigen-induced immortalization reprograms mouse cardiomyocyte progenitors with mesenchymal stem cell characteristics and osteogenic potential
por: Yu, Yichun, et al.
Publicado: (2022) -
Long noncoding RNA (lncRNA) H19: An essential developmental regulator with expanding roles in cancer, stem cell differentiation, and metabolic diseases
por: Liao, Junyi, et al.
Publicado: (2023) -
Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023) -
Transcriptomic landscape regulated by the 14 types of bone morphogenetic proteins (BMPs) in lineage commitment and differentiation of mesenchymal stem cells (MSCs)
por: Zhang, Linghuan, et al.
Publicado: (2019)